Niroshan Lokunarangoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Niroshan Lokunarangoda has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Suneth Buddhika Agampodi
International Vaccine Institute
5 shared publications - Ayesh Hettiarachchi
Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Anuradhapura, 5008, Sri Lanka
4 shared publications - Hemal Senanayake
Rajarata University of Sri Lanka
3 shared publications - Ranil Jayawardena
Faculty of Medicine, University of Colombo
3 shared publications Thilini Agampodi
Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Anuradhapura, 5008
3 shared publications- Anidu Keerthi Pathirana
Institute of Cardiology, National Hospital of Sri Lanka, Colombo, Sri Lanka
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21  (8) , e0356838
Post-acute and long-term cardiovascular effects following dengue infection: A systematic review protocol
Background and Aim: Dengue is a major arboviral disease in tropical and subtropical regions, traditionally regarded as an acute, self-limiting illness. However, emerging evidence suggests that its consequences may extend beyond the acute phase, especially involving the cardiovascular system. Reported manifestations include major adverse cardiovascular events, arrhythmias, thromboembolic complications, subclinical myocardial dysfunction, endothelial dysfunction, and vascular changes. Evidence remains fragmented due to variation in study designs, population characteristics, outcome definitions, and follow-up durations. This systematic review aims to appraise and synthesise evidence on post-acute and long-term cardiovascular outcomes following dengue infection, including their spectrum, comparative risk, and determinants. Methods and analysis: This protocol outlines a systematic review of cardiovascular outcomes in the post-acute and long-term phases of dengue infection. Human studies of any age group will be included if they report cardiovascular outcomes at least 4 weeks after acute dengue illness. Laboratory-confirmed dengue will be prioritised for primary comparative synthesis; clinically diagnosed dengue will contribute to descriptive synthesis and, where appropriate, subgroup or sensitivity analyses. Studies using cohort, case-control, cross-sectional, or case-series designs will be eligible. Comparative studies with dengue-negative or clearly defined reference controls will estimate effects where available, while non-comparative follow-up studies will contribute to descriptive synthesis. Outcomes will include major clinical cardiovascular events, including stroke or transient ischaemic attacks, subclinical cardiac or vascular abnormalities, and cardiovascular-related biomarkers. Searches will be conducted in PubMed/MEDLINE, Scopus, Cochrane Library, CINAHL, ScienceDirect, ProQuest, and Google Scholar. Two reviewers will independently perform screening, data extraction, and risk-of-bias and critical appraisal assessments. Evidence will be synthesized narratively; where comparable, random-effects meta-analysis and Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment will be conducted. PROSPERO registration: CRD420261354181. Discussion: This review will summarize post-dengue cardiovascular sequelae and identify evidence gaps. Findings may clarify post-dengue cardiovascular risk and inform future research, clinical follow-up, and public health planning in dengue-endemic settings.
- 21 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21  (8) , e0356838
Open AccessPost-acute and long-term cardiovascular effects following dengue infection: A systematic review protocol
Background and Aim: Dengue is a major arboviral disease in tropical and subtropical regions, traditionally regarded as an acute, self-limiting illness. However, emerging evidence suggests that its consequences may extend beyond the acute phase, especially involving the cardiovascular system. Reported manifestations include major adverse cardiovascular events, arrhythmias, thromboembolic complications, subclinical myocardial dysfunction, endothelial dysfunction, and vascular changes. Evidence remains fragmented due to variation in study designs, population characteristics, outcome definitions, and follow-up durations. This systematic review aims to appraise and synthesise evidence on post-acute and long-term cardiovascular outcomes following dengue infection, including their spectrum, comparative risk, and determinants. Methods and analysis: This protocol outlines a systematic review of cardiovascular outcomes in the post-acute and long-term phases of dengue infection. Human studies of any age group will be included if they report cardiovascular outcomes at least 4 weeks after acute dengue illness. Laboratory-confirmed dengue will be prioritised for primary comparative synthesis; clinically diagnosed dengue will contribute to descriptive synthesis and, where appropriate, subgroup or sensitivity analyses. Studies using cohort, case-control, cross-sectional, or case-series designs will be eligible. Comparative studies with dengue-negative or clearly defined reference controls will estimate effects where available, while non-comparative follow-up studies will contribute to descriptive synthesis. Outcomes will include major clinical cardiovascular events, including stroke or transient ischaemic attacks, subclinical cardiac or vascular abnormalities, and cardiovascular-related biomarkers. Searches will be conducted in PubMed/MEDLINE, Scopus, Cochrane Library, CINAHL, ScienceDirect, ProQuest, and Google Scholar. Two reviewers will independently perform screening, data extraction, and risk-of-bias and critical appraisal assessments. Evidence will be synthesized narratively; where comparable, random-effects meta-analysis and Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment will be conducted. PROSPERO registration: CRD420261354181. Discussion: This review will summarize post-dengue cardiovascular sequelae and identify evidence gaps. Findings may clarify post-dengue cardiovascular risk and inform future research, clinical follow-up, and public health planning in dengue-endemic settings.
- 19 May 2026
- Published by SAGE Publications in Tropical Doctor
- Vol. 56  (4) , 768-769
From chronic abscess to acute respiratory distress syndrome (ARDS): A case of recurrent melioidosis in Sri Lanka
Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and may recur months after apparent cure with fatal consequences. We report a previously healthy 31-year-old man with incompletely treated bacteraemic melioidosis who presented eight months later with recurrent chest wall abscess and fulminant pneumonia progressing to ARDS and death despite aggressive treatment.
- 19 May 2026
- Published by SAGE Publications in Tropical Doctor
- Vol. 56  (4) , 768-769
From chronic abscess to acute respiratory distress syndrome (ARDS): A case of recurrent melioidosis in Sri Lanka
Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and may recur months after apparent cure with fatal consequences. We report a previously healthy 31-year-old man with incompletely treated bacteraemic melioidosis who presented eight months later with recurrent chest wall abscess and fulminant pneumonia progressing to ARDS and death despite aggressive treatment.
- Open Access
- 25 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (3) , e0320301
Incidence of electrocardiographic and electrolyte changes in acute oleander poisoning in humans: A systematic review and meta-analysis protocol
Yellow oleander (Cascabela thevetia, previously known as Thevetia peruviana) & Common oleander (Nerium oleander) contain a wide range of cardiac glycosides and their toxicity is similar to digoxin toxicity. It causes arrhythmogenesis by directly and indirectly influencing cardiac myocytes. Oleander poisoning leads to high morbidity and mortality, causing considerable healthcare burden worldwide. This systematic review and meta-analysis aim to synthesize evidence from studies reporting the effects of electrocardiographic and biochemical changes following acute oleander toxicity. It will contribute to identifying the true incidence of electrocardiographic and electrolyte changes which will be useful in-patient management and clinical decisions. Electronic databases, Google Scholar, and reference lists of relevant articles will be searched. Human studies reporting electrolyte and electrocardiographic changes following acute yellow oleander and common oleander toxicity globally from 1988 onwards will be included. The eligibility of studies will be checked by two reviewers independently, and the risk of bias will be evaluated for each study using the JBI critical appraisal tool. The Rayyan software will be used for the systematic review while heterogeneity of studies will be assessed using I2 statistics. In the case of I2 > 50%, meta-analysis will be conducted using a random effects model using STATA software. Publication bias will be assessed using visual inspection of funnel plots & Egger’s weighted regression. The incidence of electrocardiographic and biochemical changes following oleander poisoning will directly influence patient management and guide improvements in healthcare facilities. Although ethical approval is not required for the systematic review, it will be disseminated through peer-reviewed publications, index journals, and scientific conferences. PROSPERO registration PROSPERO registration number for this protocol is CRD42023451171
- 25 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (3) , e0320301
Open AccessIncidence of electrocardiographic and electrolyte changes in acute oleander poisoning in humans: A systematic review and meta-analysis protocol
Yellow oleander (Cascabela thevetia, previously known as Thevetia peruviana) & Common oleander (Nerium oleander) contain a wide range of cardiac glycosides and their toxicity is similar to digoxin toxicity. It causes arrhythmogenesis by directly and indirectly influencing cardiac myocytes. Oleander poisoning leads to high morbidity and mortality, causing considerable healthcare burden worldwide. This systematic review and meta-analysis aim to synthesize evidence from studies reporting the effects of electrocardiographic and biochemical changes following acute oleander toxicity. It will contribute to identifying the true incidence of electrocardiographic and electrolyte changes which will be useful in-patient management and clinical decisions. Electronic databases, Google Scholar, and reference lists of relevant articles will be searched. Human studies reporting electrolyte and electrocardiographic changes following acute yellow oleander and common oleander toxicity globally from 1988 onwards will be included. The eligibility of studies will be checked by two reviewers independently, and the risk of bias will be evaluated for each study using the JBI critical appraisal tool. The Rayyan software will be used for the systematic review while heterogeneity of studies will be assessed using I2 statistics. In the case of I2 > 50%, meta-analysis will be conducted using a random effects model using STATA software. Publication bias will be assessed using visual inspection of funnel plots & Egger’s weighted regression. The incidence of electrocardiographic and biochemical changes following oleander poisoning will directly influence patient management and guide improvements in healthcare facilities. Although ethical approval is not required for the systematic review, it will be disseminated through peer-reviewed publications, index journals, and scientific conferences. PROSPERO registration PROSPERO registration number for this protocol is CRD42023451171
- 30 December 2024
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11  (1) , 015052
Machine learning based heart murmur detection and classification
Cardiovascular diseases rank among the leading causes of mortality worldwide and the early identification of diseases is of paramount importance. This work focuses on developing a novel machine learning-based framework for early detection and classification of heart murmurs by analysing phonocardiogram signals. Our heart murmur detection and classification pipeline encompasses three classification settings. We first develop a set of methods based on transfer learning to determine the existence of heart murmurs and categorize them as present, absent, or unknown. If a murmur is present it will be classified as normal or abnormal based on its clinical outcome by using 1D convolution and audio spectrogram transformers. Finally, we use Wav2Vec encoder with raw audio data and AdaBoost abstain classifier for heart murmur quality identification. Heart murmurs are categorized based on their specific attributes, including murmur pitch, murmur shape, and murmur timing which are important for diagnosis. Using the PhysioNet 2022 dataset for training and validation, we achieve an 81.08% validation accuracy for murmur presence classification and a 68.23% validation accuracy for clinical outcome classification with 60.52% sensitivity and 74.46% specificity. The suggested approaches provide a promising framework for using phonocardiogram signals for the detection, classification, and quality analysis of heart murmurs. This has significant implications for the diagnosis and treatment of cardiovascular diseases.
- 30 December 2024
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11  (1) , 015052
Machine learning based heart murmur detection and classification
Cardiovascular diseases rank among the leading causes of mortality worldwide and the early identification of diseases is of paramount importance. This work focuses on developing a novel machine learning-based framework for early detection and classification of heart murmurs by analysing phonocardiogram signals. Our heart murmur detection and classification pipeline encompasses three classification settings. We first develop a set of methods based on transfer learning to determine the existence of heart murmurs and categorize them as present, absent, or unknown. If a murmur is present it will be classified as normal or abnormal based on its clinical outcome by using 1D convolution and audio spectrogram transformers. Finally, we use Wav2Vec encoder with raw audio data and AdaBoost abstain classifier for heart murmur quality identification. Heart murmurs are categorized based on their specific attributes, including murmur pitch, murmur shape, and murmur timing which are important for diagnosis. Using the PhysioNet 2022 dataset for training and validation, we achieve an 81.08% validation accuracy for murmur presence classification and a 68.23% validation accuracy for clinical outcome classification with 60.52% sensitivity and 74.46% specificity. The suggested approaches provide a promising framework for using phonocardiogram signals for the detection, classification, and quality analysis of heart murmurs. This has significant implications for the diagnosis and treatment of cardiovascular diseases.
- Open Access
- 26 August 2024
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Neurology
- Vol. 11  (1) , 9-14
Thrombolysis with tenecteplase in acute ischaemic stroke in a tertiary care setting in Sri Lanka: A retrospective study
Introduction: Alteplase (ALT) is the standard thrombolytic treatment in acute ischaemic stroke (AIS). Tenecteplase (TNK) is proven to be effective in acute coronary syndrome, is relatively cheap, widely available and can easily be given as a single intravenous (IV) bolus. Despite evidence for its use, there is equivocal guidance for the use of TNK in AIS. On the background of a global reduction in stroke admissions, treatment interventions and prolonged treatment time metrics due to the COVID-19 pandemic, this study highlights the experience with TNK in a tertiary care setting in Sri Lanka, during the pandemic.Objectives: To describe the outcomes at 48 hours among stroke patients who underwent thrombolysis with TNK at District General Hospital Hambantota, Sri Lanka over a period of one year.Methods: We retrospectively reviewed records of adults with AIS thrombolysed with 0.25 mg/kg TNK. The National Institutes of Health Stroke Scale (NIHSS) was assessed on admission and at 24-hours following treatment. Patients were observed for 48-hours for potential adverse events.Results: We thrombolysed 20 consecutive patients over one-year. The baseline mean NIHSS was 9.7 (standard deviation (SD)=4.4; range 4-22), and the 24h-post thrombolysis mean NIHSS was 6.0 (SD=7.3; range 0-28). Seventy percent (n=14) showed an improved NIHSS of at least 1-point after thrombolysis (mean difference=3.7; SD=6.46), and 55%(n=11) displayed a major clinical improvement (change in NIHSS ≥ 4). Ten percent (n=2) developed major adverse effects (one intra-cranial haemorrhage; one haemorrhagic transformation). There were no deaths.Conclusions: TNK 0.25mg/kg for the treatment of AIS appeared efficacious and safe in our case series. The limitation in this study was the low number of patients who underwent thrombolysis during the study period, as a probable effect of the COVID-19 pandemic. Thrombolysis with TNK could be a cost-effective alternative to alteplase in resource-limited South Asian settings.
- 26 August 2024
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Neurology
- Vol. 11  (1) , 9-14
Open AccessThrombolysis with tenecteplase in acute ischaemic stroke in a tertiary care setting in Sri Lanka: A retrospective study
Introduction: Alteplase (ALT) is the standard thrombolytic treatment in acute ischaemic stroke (AIS). Tenecteplase (TNK) is proven to be effective in acute coronary syndrome, is relatively cheap, widely available and can easily be given as a single intravenous (IV) bolus. Despite evidence for its use, there is equivocal guidance for the use of TNK in AIS. On the background of a global reduction in stroke admissions, treatment interventions and prolonged treatment time metrics due to the COVID-19 pandemic, this study highlights the experience with TNK in a tertiary care setting in Sri Lanka, during the pandemic.Objectives: To describe the outcomes at 48 hours among stroke patients who underwent thrombolysis with TNK at District General Hospital Hambantota, Sri Lanka over a period of one year.Methods: We retrospectively reviewed records of adults with AIS thrombolysed with 0.25 mg/kg TNK. The National Institutes of Health Stroke Scale (NIHSS) was assessed on admission and at 24-hours following treatment. Patients were observed for 48-hours for potential adverse events.Results: We thrombolysed 20 consecutive patients over one-year. The baseline mean NIHSS was 9.7 (standard deviation (SD)=4.4; range 4-22), and the 24h-post thrombolysis mean NIHSS was 6.0 (SD=7.3; range 0-28). Seventy percent (n=14) showed an improved NIHSS of at least 1-point after thrombolysis (mean difference=3.7; SD=6.46), and 55%(n=11) displayed a major clinical improvement (change in NIHSS ≥ 4). Ten percent (n=2) developed major adverse effects (one intra-cranial haemorrhage; one haemorrhagic transformation). There were no deaths.Conclusions: TNK 0.25mg/kg for the treatment of AIS appeared efficacious and safe in our case series. The limitation in this study was the low number of patients who underwent thrombolysis during the study period, as a probable effect of the COVID-19 pandemic. Thrombolysis with TNK could be a cost-effective alternative to alteplase in resource-limited South Asian settings.
- Open Access
- 30 April 2024
- Published by Sri Lanka Journals Online in Anuradhapura Medical Journal
- Vol. 18  (1) , 01-04
Empowering the youth with national strategy: The imperative of basic life support training in combating sudden cardiac arrests
- 30 April 2024
- Published by Sri Lanka Journals Online in Anuradhapura Medical Journal
- Vol. 18  (1) , 01-04
Open AccessEmpowering the youth with national strategy: The imperative of basic life support training in combating sudden cardiac arrests
- Open Access
- 29 February 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 1028
Disease burden of cardiovascular conditions complicating pregnancy in Sri Lanka: a protocol
Background Cardiovascular diseases (CVD) are the commonest indirect medical cause of maternal deaths worldwide, both in high-income and low and middle-income countries. To minimize the effects of CVD in pregnancy, proper risk assessment and appropriate referral is required. In Sri Lanka, cardiovascular disease complicating pregnancy is a significant cause of maternal mortality, second only to postpartum hemorrhage. Screening for CVD in pregnancy in Sri Lanka is limited to a routine clinical assessment. Evidence-based guidelines are yet to be developed, and this deficit may have resulted in a substantial underestimation of the CVD burden. This study aims to determine the burden of CVD in early pregnancy and develop a risk prediction model to be used in field pregnancy clinics in Sri Lanka to reduce CVD effects in pregnancy. Methods A prospective cohort study was carried out in the Anuradhapura district, Sri Lanka. Following registration to the antenatal care, pregnant women fulfilling the eligibility criteria were invited to attend a special clinic at their relevant Medical Officer of Health (MOH) area. Risk assessment was done through history and a clinical examination, and suspected/probable cases were referred for an echocardiogram by a consultant cardiologist. All the recruited participants in the first trimester were prospectively followed up and screened again between 24–28 weeks of the period of amenorrhoea (POA). Antenatal ward admissions with CVD complicating pregnancy will be extracted, and a telephone interview will be carried out between 6–12 weeks after the expected delivery date to cover postpartum morbidities. Discussion This proposed study will be the largest of its kind carried out in the local setting. The study's findings will be beneficial for policymakers to develop guidelines to reduce maternal cardiovascular disease morbidities and mortalities in Sri Lanka.
- 29 February 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 1028
Open AccessDisease burden of cardiovascular conditions complicating pregnancy in Sri Lanka: a protocol
Background Cardiovascular diseases (CVD) are the commonest indirect medical cause of maternal deaths worldwide, both in high-income and low and middle-income countries. To minimize the effects of CVD in pregnancy, proper risk assessment and appropriate referral is required. In Sri Lanka, cardiovascular disease complicating pregnancy is a significant cause of maternal mortality, second only to postpartum hemorrhage. Screening for CVD in pregnancy in Sri Lanka is limited to a routine clinical assessment. Evidence-based guidelines are yet to be developed, and this deficit may have resulted in a substantial underestimation of the CVD burden. This study aims to determine the burden of CVD in early pregnancy and develop a risk prediction model to be used in field pregnancy clinics in Sri Lanka to reduce CVD effects in pregnancy. Methods A prospective cohort study was carried out in the Anuradhapura district, Sri Lanka. Following registration to the antenatal care, pregnant women fulfilling the eligibility criteria were invited to attend a special clinic at their relevant Medical Officer of Health (MOH) area. Risk assessment was done through history and a clinical examination, and suspected/probable cases were referred for an echocardiogram by a consultant cardiologist. All the recruited participants in the first trimester were prospectively followed up and screened again between 24–28 weeks of the period of amenorrhoea (POA). Antenatal ward admissions with CVD complicating pregnancy will be extracted, and a telephone interview will be carried out between 6–12 weeks after the expected delivery date to cover postpartum morbidities. Discussion This proposed study will be the largest of its kind carried out in the local setting. The study's findings will be beneficial for policymakers to develop guidelines to reduce maternal cardiovascular disease morbidities and mortalities in Sri Lanka.
- Open Access
- 6 June 2023
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 15, 100223
Heart disease complicating pregnancy as a leading cause of maternal deaths in LMIC settings: the Sri Lankan experience
- 6 June 2023
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 15, 100223
Open AccessHeart disease complicating pregnancy as a leading cause of maternal deaths in LMIC settings: the Sri Lankan experience
- Open Access
- 12 June 2022
- Published by Elsevier in Data in Brief
- Vol. 43, 108378
Demographic, exposure, clinical, biochemical and diagnostic data of febrile patients recruited for the largest field study on leptospirosis in Sri Lanka
- 12 June 2022
- Published by Elsevier in Data in Brief
- Vol. 43, 108378
Open AccessDemographic, exposure, clinical, biochemical and diagnostic data of febrile patients recruited for the largest field study on leptospirosis in Sri Lanka
- Open Access
- 15 March 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 1028
Disease burden of cardiovascular conditions complicating pregnancy in Sri Lanka: a protocol
Background Cardiovascular diseases (CVD) are the commonest indirect medical cause of maternal deaths worldwide, both in high-income and low and middle-income countries. To minimize the effects of CVD in pregnancy, proper risk assessment and appropriate referral is required. In Sri Lanka, cardiovascular disease complicating pregnancy is a significant cause of maternal mortality, second only to postpartum hemorrhage. Screening for CVD in pregnancy in Sri Lanka is limited to a routine clinical assessment. Evidence-based guidelines are yet to be developed, and this deficit may have resulted in a substantial underestimation of the CVD burden. This study aims to determine the burden of CVD in early pregnancy and develop a risk prediction model to be used in field pregnancy clinics in Sri Lanka to reduce CVD effects in pregnancy. Methods A prospective cohort study was carried out in the Anuradhapura district, Sri Lanka. Following registration to the antenatal care, pregnant women fulfilling the eligibility criteria were invited to attend a special clinic at their relevant Medical Officer of Health (MOH) area. Risk assessment was done through history and a clinical examination, and suspected/probable cases were referred for an echocardiogram by a consultant cardiologist. All the recruited participants in the first trimester were prospectively followed up and screened again between 24–28 weeks of the period of amenorrhoea (POA). Antenatal ward admissions with CVD complicating pregnancy will be extracted, and a telephone interview will be carried out between 6–12 weeks after the expected delivery date to cover postpartum morbidities. Discussion This proposed study will be the largest of its kind carried out in the local setting. The study's findings will be beneficial for policymakers to develop guidelines to reduce maternal cardiovascular disease morbidities and mortalities in Sri Lanka.
- 15 March 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 1028
Open AccessDisease burden of cardiovascular conditions complicating pregnancy in Sri Lanka: a protocol
Background Cardiovascular diseases (CVD) are the commonest indirect medical cause of maternal deaths worldwide, both in high-income and low and middle-income countries. To minimize the effects of CVD in pregnancy, proper risk assessment and appropriate referral is required. In Sri Lanka, cardiovascular disease complicating pregnancy is a significant cause of maternal mortality, second only to postpartum hemorrhage. Screening for CVD in pregnancy in Sri Lanka is limited to a routine clinical assessment. Evidence-based guidelines are yet to be developed, and this deficit may have resulted in a substantial underestimation of the CVD burden. This study aims to determine the burden of CVD in early pregnancy and develop a risk prediction model to be used in field pregnancy clinics in Sri Lanka to reduce CVD effects in pregnancy. Methods A prospective cohort study was carried out in the Anuradhapura district, Sri Lanka. Following registration to the antenatal care, pregnant women fulfilling the eligibility criteria were invited to attend a special clinic at their relevant Medical Officer of Health (MOH) area. Risk assessment was done through history and a clinical examination, and suspected/probable cases were referred for an echocardiogram by a consultant cardiologist. All the recruited participants in the first trimester were prospectively followed up and screened again between 24–28 weeks of the period of amenorrhoea (POA). Antenatal ward admissions with CVD complicating pregnancy will be extracted, and a telephone interview will be carried out between 6–12 weeks after the expected delivery date to cover postpartum morbidities. Discussion This proposed study will be the largest of its kind carried out in the local setting. The study's findings will be beneficial for policymakers to develop guidelines to reduce maternal cardiovascular disease morbidities and mortalities in Sri Lanka.